Regulus Therapeutics Inc. (RGLS)
After hours:
| Previous Close | 2.5200 |
| Open | 2.5100 |
| Bid | 2.2900 x 200 |
| Ask | 2.3400 x 500 |
| Day's Range | 2.3000 - 2.5893 |
| 52 Week Range | 1.0800 - 3.7900 |
| Volume | |
| Avg. Volume | 3,176,808 |
| Market Cap | 150.57M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.
- PR Newswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
- PR Newswire
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Pa
